CSPC PHARMA (01093) has received a $25 million research and development milestone payment from AstraZeneca under a strategic collaboration and licensing agreement.

22:33 10/07/2026

Sinopharm Group (01093) announced that they have signed a strategic cooperation and authorization agreement with AstraZeneca to utilize the group's long-acting drug delivery technology platform and peptide drug AI discovery platform to develop innovative long-acting peptide drugs. The board of directors gladly announced that following the receipt of the first payment under the agreement on May 29, 2026, the group received a $25 million research milestone payment from AstraZeneca on July 10, 2026. The achievement of this milestone signifies that the related research and development work under the agreement is progressing steadily according to plan.

CSPC Pharma (01093) announced that the group has signed a strategic cooperation and licensing agreement with AstraZeneca to utilize the group's long-acting delivery technology platform and peptide drug AI discovery platform to develop innovative long-acting peptide drugs. The board of directors happily announced that following the receipt of the initial payment under this agreement on May 29, 2026, the group received a $25 million research milestone payment from AstraZeneca on July 10, 2026. The achievement of this milestone marks the steady progress of the related research and development work under this agreement according to plan.

US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.

GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.

SHIFANG HLDG(01831) clarification: The rumors of intending to invest in "Fuzhou Xiangshang Maternity Center" and assuming the unpaid wages of employees of this project are not true.

US Stock Market Move | Concept stocks related to optical communication generally fell, with Applied Optoelectronics (AAOI.US) dropping more than 6%.

GUMING (01364) spent HK$5.758 million to repurchase 288,000 shares on July 10th.

SHIFANG HLDG(01831) clarification: The rumors of intending to invest in "Fuzhou Xiangshang Maternity Center" and assuming the unpaid wages of employees of this project are not true.